Anti-IL-5 [Sch 55700 (Reslizumab)]
Catalogue Number: AB04156-3.3-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | IL5; Interleukin-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; CDP-835; CDP835; h39D10; JES1-39D10; SCH55700 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 0.1 mg |
| Host name: | Mouse |
| Clone: | Sch 55700 (Reslizumab) |
| Isotype: | IgG2b |
| Immunogen: | The parental rat antibody 39D10 was generated by immunizing a male lewis rat with semi-purified recombinant mammalian-expressed IL-5. The original Sch 55700 antibody was generated by grafting CDRs of the original rat antibody on to human framework regions. |
| Application: | NT, Blk, Inh |
Additional Text
Gene ID
3567
Gene Name
IL5
Uniprot ID
P05113
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Application Notes
This antibody is a humanized version of anti-IL5 rat antibody 39D10. The binding affinity of the original human IgG4 version of this antibody was measured using Biacore analysis and it was reported that this antibody bound human IL-5 with a Kd= 81pM (PMID: 7613159). This antibody was capable of inhibiting the binding of hIL-5 to Ba/F3 cells and IL5 induced proliferation of human erythroleukemic cell line TF-1 with an EC50 of 45pM. The in vivo activity of this antibody was studied in Ascaris responsive monkeys, and it was reported that this antibody inhibits eosinophilia in allergic animal models with an extended biological duration (PMID: 7613159). This antibody was active against lung eosinophilia in allergic monkeys and mice and against pulmonary eosinophilia and airway hyperresponsiveness in allergic guinea pigs. It was reported that this antibody did not cause immunosuppression in guinea pigs (PMID: 9698918). It also blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs. In allergic rabbits, this antibody blocks cutaneous eosinophilia. In allergic cynomolgus monkeys, a single dose of this antibody (0.3 mg/kg i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months (PMID: 10514907). A study was also conducted to determine the effect of this antibody in patients with severe persistent asthma (PMID: 12649124). Clinical trials were conducted with this antibody to reduce asthma exacerbations, control asthma-related symptoms and improve pulmonary function in patients with eosinophilic asthma (PMID: 26372797).
Short Description
This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques.
AB04156-3.3 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations